Abstract
Glioblastoma (GBM) is the most lethal tumor of the Central Nervous System (CNS), with an overall median survival of around 15 months. The efficacy of conventional quarterly treatment is limited by both chemoresistance and the invasive and diffuse nature of the tumor, resulting in frequent relapses. Thus, biomarker-based approaches should be explored in the search for new therapeutic targe…